Treatment of chronic kidney disease

Kidney International

Volumn 81, Issue 4, 2012, Pages 351-362

  Turner, Jeffrey M ^a   Bauer, Carolyn ^a   Abramowitz, Matthew K ^a   Melamed, Michal L ^a   Hostetter, Thomas H ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; chronic renal disease; chronic renal insufficiency

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALLOPURINOL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; ATRASENTAN; AVOSENTAN; BARDOXOLONE METHYL; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METFORMIN; PARICALCITOL; PHOSPHATE BINDING AGENT; PIRFENIDONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THIAZIDE DIURETIC AGENT; VITAMIN D;

ACIDOSIS; ALBUMINURIA; ANEMIA; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; KIDNEY FAILURE; KIDNEY FIBROSIS; LIVER CIRRHOSIS; LUNG FIBROSIS; METABOLIC DISORDER; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION; PATHOGENESIS; PATIENT EDUCATION; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

EID: 84856436794     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.380     Document Type: Review

References (149)

1. Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin Nephrol 2003; 23: 194-199. (Pubitemid 36397101)
2. Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin North Am 2005; 89: 489-509. (Pubitemid 40332394)
3. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296. (Pubitemid 43228342)
4. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with allcause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-1352.
6. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
7. Zatz R, Anderson S, Meyer TW et al. Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int Suppl 1987; 20: S123-S129. (Pubitemid 17072341)
8. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87. (Pubitemid 32661190)
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
10. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
11. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
12. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289. (Pubitemid 26058479)
13. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996; 39: 587-593.
14. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
15. Appel LJ, Wright Jr JT, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929.
16. Jafar TH, Stark PC, Schmid CH et al. The effect of angiotensin- convertingenzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67: 265-271. (Pubitemid 40019248)
17. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALTPKD studies. Clin J Am Soc Nephrol 2008; 3: 1197-1204.
18. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 462-465; discussion 466-467.
19. Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells. J Am Soc Nephrol 2003; 14(Suppl 1): S36-S41. (Pubitemid 36687038)
20. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006 17 2974-2984. (Pubitemid 44707757)
21. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991. (Pubitemid 44707758)
22. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783.
23. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991. (Pubitemid 44707758)
24. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006; 100: 9-16. (Pubitemid 43161608)
25. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124. (Pubitemid 36092015)
26. Kunz R, Wolbers M, Glass T et al. The COOPERATE trial: a letter of concern. Lancet 2008; 371: 1575-1576. (Pubitemid 351626834)
27. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 2006; 26: 629, 632; author reply 629-632.
28. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
29. Fried LF, Duckworth W, Zhang JH et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368.
30. Ponda MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 668-677.
31. Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
32. Navaneethan SD, Nigwekar SU, Sehgal AR et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009: CD007004.
33. Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
34. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
35. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
36. Upadhyay A, Earley A, Haynes SM et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154: 541-548.
37. Cushman WC, Evans GW, Byington RP et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585.
38. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007.
39. Dussol B, Moussi-Frances J, Morange S et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349-353. (Pubitemid 40276891)
40. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720.
41. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008 25(Suppl 2) 25-29. (Pubitemid 352020092)
42. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376: 419-430.
43. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
44. de Boer IH, Rue TC, Cleary PA et al. Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria: An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort. Arch Intern Med 171: 412-420.
45. Van Slyke DD, Linder GC, Hiller A et al. The excretion of ammonia and titratable acid in nephritis. J Clin Invest 1926; 2: 255-288.
46. Simpson DP. Control of hydrogen ion homeostasis and renal acidosis. Medicine (Baltimore) 1971; 50: 503-541.
47. Simon E, Martin D, Buerkert J. Contribution of individual superficial nephron segments to ammonium handling in chronic metabolic acidosis in the rat. Evidence for ammonia disequilibrium in the renal cortex. J Clin Invest 1985; 76: 855-864. (Pubitemid 15023144)
48. Schoolwerth AC, Sandler RS, Hoffman PM et al. Effects of nephron reduction and dietary protein content on renal ammoniagenesis in the rat. Kidney Int 1975; 7: 397-404.
49. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76:
50. Tolins JP, Hostetter MK, Hostetter TH. Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest 1987; 79: 1447-1458. (Pubitemid 17099649)
51. Torres VE, Cowley Jr BD, Branden MG et al. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 2001; 9: 171-180. (Pubitemid 32429677)
52. Throssell D, Brown J, Harris KP et al. Metabolic acidosis does not contribute to chronic renal injury in the rat. Clin Sci (Lond) 1995; 89: 643-650.
53. Throssell D, Harris KP, Bevington A et al. Renal effects of metabolic acidosis in the normal rat. Nephron 1996; 73: 450-455. (Pubitemid 26229701)
54. Shah SN, Abramowitz M, Hostetter TH et al. Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis 2009; 54: 270-277.
55. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysisdependent CKD. Nephrol Dial Transplant 2009; 24: 1232-1237.
56. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084.
57. Mahajan A, Simoni J, Sheather SJ et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010; 78: 303-309.
58. Phisitkul S, Khanna A, Simoni J et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010; 77: 617-623.
59. Wesson DE, Simoni J, Broglio K et al. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 2011; 300: F830-F837.
60. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435.
61. Alfrey AC. The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int Suppl 2004; 66: S13-S17. (Pubitemid 39121054)
62. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol 2009; 4: 1136-1139.
63. Levin A, Djurdjev O, Beaulieu M et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671.
64. Tonelli M, Curhan G, Pfeffer M et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009; 120: 1784-1792.
65. Eddington H, Hoefield R, Sinha S et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 2251-2257.
66. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. Jama 305: 1119-1127.
67. Bellasi A, Mandreoli M, Baldrati L et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-tomoderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 883-891.
68. Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-247.
69. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
70. Hruska KA, Mathew S, Lund RJ et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol 2009; 29: 156-165.
71. Melamed ML, Astor B, Michos ED et al. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
72. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 78: 146-151.
73. Zhang Y, Kong J, Deb DK et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21: 966-973.
74. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376: 1543-1551.
75. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial 2009; 22: 363-368.
76. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
77. Wen CP, David Cheng TY, Chan HT et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 56: 273-288.
78. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis 56: 247-250.
79. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama 2008; 300: 924-932.
80. Obermayr RP, Temml C, Gutjahr G et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407-2413.
81. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59. (Pubitemid 41828266)
82. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
83. Parfrey PS. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. Curr Opin Nephrol Hypertens 20: 177-181.
84. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
85. Woods LL. Mechanisms of renal hemodynamic regulation in response to protein feeding. Kidney Int 1993; 44: 659-675. (Pubitemid 23290506)
86. Nakamura T, Fukui M, Ebihara I et al. Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis. Kidney Int 1994; 45: 1593-1605. (Pubitemid 24207494)
87. Curhan GC, Mitch WE In: Brenner BM (ed). The Kidney, 8th edn. Saunders: Philadelphia, PA, 2008, pp 1817-1847.
88. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009: CD001892.
89. Moorhead JF, Chan MK, El-Nahas M et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311. (Pubitemid 13240921)
90. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43: 218-225. (Pubitemid 23167469)
91. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl 2000; 75: S27-S31. (Pubitemid 30205436)
92. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 1999; 12: 33-40. (Pubitemid 29059164)
93. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl 1999; 71: S51-S53. (Pubitemid 29304813)
94. Kasiske BL, ODonnell MP, Schmitz PG et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37: 880-891. (Pubitemid 20089220)
95. Guijarro C, Kasiske BL, Kim Y et al. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995; 26: 152-161.
96. Ravid M, Brosh D, Ravid-Safran D et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004. (Pubitemid 28213577)
97. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091. (Pubitemid 36909916)
98. Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 1402-1407. (Pubitemid 36929170)
99. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008; 74: 571-576.
100. Ota T, Takamura T, Ando H et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-851. (Pubitemid 36831414)
101. Kasiske BL, ODonnell MP, Cleary MP et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672. (Pubitemid 18083115)
102. Li C, Lim SW, Choi BS et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 2005; 25: 611-620. (Pubitemid 41816056)
103. Zhang W, Liu M, Wu Y et al. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res 2007; 143: 428-436. (Pubitemid 350101566)
104. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016. (Pubitemid 44036185)
105. Douglas K, OMalley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124. (Pubitemid 46780585)
106. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
107. RamachandraRao SP, Zhu Y, Ravasi T et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
108. Shimizu T, Fukagawa M, Kuroda T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney International Supplement 1997; 63: S239-S243.
109. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 2005; 11: 149-158. (Pubitemid 40403252)
110. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-1665. (Pubitemid 44629221)
111. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047. (Pubitemid 40616955)
112. Cho ME, Smith DC, Branton MH et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
113. Sharma K, Ix JH, Mathew AV et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151.
114. Sporn MB, Liby KT, Yore MM et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011; 74: 537-545.
115. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
116. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17: 943-955.
117. Brochu E, Lacasse S, Moreau C et al. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 1999; 14: 1881-1888. (Pubitemid 29358883)
118. Wolf SC, Brehm BR, Gaschler F et al. Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 4): 29-30. (Pubitemid 29358858)
119. Goddard J, Johnston NR, Hand MF et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193. (Pubitemid 38332625)
120. Mann JF, Green D, Jamerson K et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535.
121. Kohan DE, Pritchett Y, Molitch M et al. Addition of atrasentan to reninangiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763-772.
122. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
123. Daroux M, Prevost G, Maillard-Lefebvre H et al. Advanced glycation endproducts: implications for diabetic and non-diabetic nephropathies. Diabetes Metab 2010; 36: 1-10.
124. Izuhara Y, Nangaku M, Takizawa S et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 2008; 23: 497-509. (Pubitemid 351767619)
125. Brownlee M, Vlassara H, Kooney A et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632. (Pubitemid 16095602)
126. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950. (Pubitemid 34175462)
127. Babaei-Jadidi R, Karachalias N, Ahmed N et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120. (Pubitemid 36919806)
128. Wilkinson-Berka JL, Kelly DJ, Koerner SM et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-3289. (Pubitemid 35246975)
129. Figarola JL, Loera S, Weng Y et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 2008; 51: 882-891.
130. Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40. (Pubitemid 38250484)
131. Williams ME, Bolton WK, Khalifah RG et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27: 605-614. (Pubitemid 350014947)
132. Stirban A, Negrean M, Stratmann B et al. Benfotiamine prevents macroand microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071. (Pubitemid 44871188)
133. Little WC, Zile MR, Kitzman DW et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195. (Pubitemid 40462421)
134. Snyder JJ, Collins AJ. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol 2009; 20: 1614-1622.
135. Lee W, Campoy S, Smits G et al. Effectiveness of a chronic kidney disease clinic in achieving K/DOQI guideline targets at initiation of dialysis-a single-centre experience. Nephrol Dial Transplant 2007; 22: 833-838. (Pubitemid 46351693)
136. Yeoh HH, Tiquia HS, Abcar AC et al. Impact of predialysis care on clinical outcomes. Hemodial Int 2003; 7: 338-341.
137. Levin A, Lewis M, Mortiboy P et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 1997; 29: 533-540. (Pubitemid 27155273)
138. Wei SY, Chang YY, Mau LW et al. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology (Carlton) 2010; 15: 108-115.
139. U.S. Renal Data System. USRDS 2009 Annual Data Report: Atlas of End- Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2009.
140. Devins GM, Mendelssohn DC, Barre PE et al. Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis 2003; 42: 693-703. (Pubitemid 37187369)
141. Richards N, Harris K, Whitfield M et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008; 23: 549-555. (Pubitemid 351767656)
142. Bayliss EA, Bhardwaja B, Ross C et al. Multidisciplinary team care may slow the rate of decline in renal function. Clin J Am Soc Nephrol 2011.
143. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003; 41: 310-318. (Pubitemid 36152448)
144. Chen SC, Hwang SJ, Tsai JC et al. Early nephrology referral is associated with prolonged survival in hemodialysis patients even after exclusion of lead-time bias. Am J Med Sci 2010; 339: 123-126.
145. Curtis BM, Ravani P, Malberti F et al. The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant 2005; 20: 147-154. (Pubitemid 40207620)
146. Goldstein M, Yassa T, Dacouris N et al. Multidisciplinary predialysis care and morbidity and mortality of patients on dialysis. Am J Kidney Dis 2004; 44: 706-714. (Pubitemid 39237615)
147. Hemmelgarn BR, Manns BJ, Zhang J et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 993-999. (Pubitemid 46434517)
148. Bielesz B, Sirin Y, Si H et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010; 120: 4040-4054.
149. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.